Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Soligenix Inc SNGX

Healthcare Biotechnology

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe... see more

Add To Watchlist

Recent & Breaking News (NDAQ:SNGX)

Soligenix, Inc. to Present at the virtual Fall Investor Summit on November 16th-18th

Accesswire November 12, 2020

Soligenix Announces Recent Accomplishments And Third Quarter 2020 Financial Results

PR Newswire November 12, 2020

Soligenix Invited to Present at Upcoming Virtual Investor Conferences

PR Newswire November 10, 2020

Soligenix Announces Phase 3 FLASH Study Continues to Demonstrate Positive Benefits in Patients with Cutaneous T-Cell Lymphoma

PR Newswire October 22, 2020

Soligenix to Present at the BIO Investor Forum

PR Newswire October 8, 2020

Soligenix's RiVax(R) Program Back in Focus After Deadly Ricin Toxin Intercepted Before Reaching White House

Newsfile September 21, 2020

Soligenix Announces Publication Demonstrating Thermostabilization of Filovirus Vaccine Antigens

PR Newswire September 15, 2020

Soligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax(TM) Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine

PR Newswire September 10, 2020

Soligenix Invited to Present at Upcoming Virtual Investor Conferences

PR Newswire September 9, 2020

Soligenix Announces Investor Webcast Event: Advantages of the CiVax(TM) Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine

PR Newswire September 3, 2020

LD Micro - 360 Companies Set to Present - this Week

Accesswire August 31, 2020

Soligenix to Present at the LD Micro Conference

PR Newswire August 27, 2020

Soligenix Announces Recent Accomplishments And Second Quarter 2020 Financial Results

PR Newswire August 14, 2020

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Soligenix, Inc. for Potential Breach of Fiduciary Duty Claims

ACCESSWIRE IA August 12, 2020

Soligenix Announces Publication of Positive Pre-clinical Results for a Novel COVID-19 Vaccine

PR Newswire July 28, 2020

Soligenix Issues Corporate Update - Highlights Important Catalysts for Second Half of 2020

PR Newswire July 20, 2020

Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis

PR Newswire June 24, 2020

Soligenix to Join Russell Microcap® Index

PR Newswire June 22, 2020

Soligenix to Present at the MedInvest Infectious Disease and Immunology Investor Conference

PR Newswire June 9, 2020

Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results

PR Newswire May 15, 2020